BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17483245)

  • 1. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
    Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
    Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
    Källström AC; Salme R; Rydén L; Nordenskjöld B; Jönsson PE; Stål O
    Eur J Cancer; 2010 Mar; 46(5):892-900. PubMed ID: 20060711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ;
    Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
    J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of cyclin E in low-risk node negative breast cancer.
    Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
    Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
    Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
    Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
    J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of cyclin E expression in operable breast cancer.
    Potemski P; Kusińska R; Pasz-Walczak G; Piekarski JH; Watała C; Płuciennik E; Bednarek AK; Kordek R
    Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
    Jirström K; Rydén L; Anagnostaki L; Nordenskjöld B; Stål O; Thorstenson S; Chebil G; Jönsson PE; Fernö M; Landberg G
    J Clin Pathol; 2005 Nov; 58(11):1135-42. PubMed ID: 16254100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.